Precision BioSciences Inc (DTIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has a cash flow conversion efficiency ratio of -0.297x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.44 Million) by net assets ($45.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Precision BioSciences Inc stock valuation for the company's overall valuation and market capitalisation.
Precision BioSciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Precision BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precision BioSciences Inc ranked by their cash flow conversion efficiency. Explore how high is Precision BioSciences Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
0.002x |
|
XRF Scientific Ltd
AU:XRF
|
0.104x |
|
Polymetals Resources Ltd
AU:POL
|
-1.678x |
|
Bank Woori Saudara Indonesia 1906
JK:SDRA
|
-0.049x |
|
Chesapeake Gold Corp.
V:CKG
|
-0.008x |
|
Netfonds AG
XETRA:NF4
|
0.058x |
|
GoPro Inc
NASDAQ:GPRO
|
0.204x |
|
Groupe Sfpi
PA:SFPI
|
0.132x |
Annual Cash Flow Conversion Efficiency for Precision BioSciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Precision BioSciences Inc from 2016 to 2025. View Precision BioSciences Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $92.25 Million | $-65.84 Million | -0.714x | +31.13% |
| 2024-12-31 | $56.39 Million | $-58.45 Million | -1.036x | +76.76% |
| 2023-12-31 | $18.86 Million | $-84.11 Million | -4.460x | -489.06% |
| 2022-12-31 | $60.43 Million | $-45.75 Million | -0.757x | -535.97% |
| 2021-12-31 | $91.17 Million | $-10.85 Million | -0.119x | +93.95% |
| 2020-12-31 | $44.42 Million | $-87.39 Million | -1.967x | -269.47% |
| 2019-12-31 | $138.31 Million | $-73.64 Million | -0.532x | +58.87% |
| 2018-12-31 | $39.96 Million | $-51.72 Million | -1.294x | -241.22% |
| 2017-12-31 | $-26.37 Million | $-24.17 Million | 0.917x | +104.72% |
| 2016-12-31 | $-4.75 Million | $92.27 Million | -19.430x | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more